GlassScriptPhysician profile
Alejandro N Martinez
NPI 1659352953
$4,870.32
in general payments reported to CMS, 2019-2025
32 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,966 · 2020: $158 · 2022: $414 · 2023: $1,133 · 2024: $671 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,253 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.63 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,114.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $494.92 | 2019-2025 | |
| Lilly USA, LLC | $352.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $330.27 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $289.18 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $263.68 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $243.45 | 2019-2025 | |
| Glaxosmithkline, LLC. | $219.38 | 2019-2024 | Trelegy Ellipta |
| Dexcom, INC. | $184.44 | 2023-2025 | Dexcom G6 Transmitter |
| C. R. Bard, INC. & Subsidiaries | $163.53 | 2019 | |
| Exact Sciences Corporation | $149.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $128.21 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $111.44 | 2019 | |
| United Therapeutics Corporation | $98.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $90.37 | 2019-2023 | Breztri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.94 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $68.07 | 2019 | |
| Alnylam Pharmaceuticals INC. | $65.65 | 2022-2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $65.54 | 2022-2023 | |
| Abbott Laboratories | $49.67 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $47.22 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $44.29 | 2023-2024 | Eliquis |
| Sanofi-Aventis U.S. LLC | $44.11 | 2019 | |
| Amarin Pharma, INC. | $38.47 | 2019-2020 | |
| Sanofi Pasteur INC. | $21.14 | 2019 | |
| Almatica Pharma LLC | $16.98 | 2023 | Loreev Xr, Gralise |
| Avanir Pharmaceuticals, INC. | $16.59 | 2019 | |
| Vapotherm INC | $14.96 | 2025 | Vapotherm |
| Ironwood Pharmaceuticals, INC | $14.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.81 | 2023 | Jardiance |
| Cvrx, INC. | $12.70 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.